H.R. 3271 would codify certain requirements with respect to Medicare coverage of diabetic testing supplies (DTS). Based on current Medicare program and payment rules for DTS, CBO estimates that enacting H.R. 3271 would have no effect on the federal budget.
Enacting H.R. 3271 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply. CBO estimates that enacting H.R. 3271 would not increase net direct spending or on-budget deficits in one or more of the four consecutive 10-year periods beginning in 2028.
H.R. 3271 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.
